{
  "nctId": "NCT04803370",
  "briefTitle": "Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma",
  "officialTitle": "Study of the Efficacy of Reinforcing of the Standard Therapy in COVID-19 Patients With Repeated Transfusion of Immune Plasma From COVID-19 Convalescents vs Exclusive Standard Therapy in Hospitalized COVID-19 Patients",
  "protocolDocument": {
    "nctId": "NCT04803370",
    "filename": "Prot_SAP_ICF_000.pdf",
    "label": "Study Protocol, Statistical Analysis Plan, and Informed Consent Form",
    "date": "2020-09-03",
    "uploadDate": "2023-11-09T14:48",
    "size": 1609244,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04803370/document/Prot_SAP_ICF_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": true
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 55,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2020-07-08",
    "completionDate": "2021-09-01",
    "primaryCompletionDate": "2021-09-01",
    "firstSubmitDate": "2021-03-09",
    "firstPostDate": "2021-03-17"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Ability to understand the HIP and sign the study IC\n* male or female =/\\> 18 years\n* Patient hospitalized with a COVID-19 diagnosis by PCR on nasopharyngeal swabs or any other biological sample.\n* Presence of respiratory symptoms and / or fever associated with COVID-19, with clinical evolution time for COVID-19 equal to or less than 7 days.\n* Presence of pneumonia on chest X-ray and / or SatO2 \\<94% aa.\n* Sequential Organ Failure Assessment (SOFA) score â‰¤ 6.\n* Accept the condition of complying with the procedures established in the protocol.\n\nExclusion Criteria:\n\n* Patients with a previous history of allergic transfusion reaction.\n* Lactating or pregnant women and a positive pregnancy test.\n* Patients who have been treated with plasma in the 21 days prior to the screening / baseline visit.\n* Patients who are at the time of study, participating in another clinical trial.\n* Patients who haven't completed all study procedures.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Adaptive COVID-19 Treatment Trial Scale (ACTT) Version II",
        "description": "The scale provides a measure of COVID-19 severity based on the patient's physical situation, whose design was based on a blueprint of the WHO in treating COVID-19.\n\n* 1= Death\n* 2= Hospitalized. on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)\n* 3= Hospitalized. on non-invasive ventilation or high flow oxygen devices\n* 4= Hospitalized. requiring supplemental oxygen\n* 5= Hospitalized. not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)\n* 6= Hospitalized. not requiring supplemental oxygen - no longer requiring ongoing medical care.\n* 7= Not hospitalized. limitation on activities and/or requiring home oxygen\n* 8= Not hospitalized. no limitations on activities.",
        "timeFrame": "Day 7"
      },
      {
        "measure": "Adaptive COVID-19 Treatment Trial Scale (ACTT) Version II",
        "description": "The scale provides a measure of COVID-19 severity based on the patient's physical situation, whose design was based on a blueprint of the WHO in treating COVID-19.\n\n* 1= Death\n* 2= Hospitalized. on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)\n* 3= Hospitalized. on non-invasive ventilation or high flow oxygen devices\n* 4= Hospitalized. requiring supplemental oxygen\n* 5= Hospitalized. not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)\n* 6= Hospitalized. not requiring supplemental oxygen - no longer requiring ongoing medical care.\n* 7= Not hospitalized. limitation on activities and/or requiring home oxygen\n* 8= Not hospitalized. no limitations on activities.",
        "timeFrame": "Day 14"
      }
    ],
    "secondary": [
      {
        "measure": "Anti-SARS-CoV-2 S IgG Serum Titer",
        "description": "The levels of Anti-SARS-CoV-2 S IgG serum",
        "timeFrame": "At inclusion, Day 21"
      },
      {
        "measure": "Time of Hospitalization",
        "description": "time that the patients have passed in the hospital.",
        "timeFrame": "Day 21"
      },
      {
        "measure": "Time to Negativization of RT-PCR",
        "description": "total time elapsed until negative RT-PCR test",
        "timeFrame": "Day 21"
      },
      {
        "measure": "Diastolic Blood Pressure",
        "description": "the pressure of blood in the artery when the heart relaxes between beats.",
        "timeFrame": "At inclusion, Day 1, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "Systolic Blood Pressure",
        "description": "The pressure of blood in the artery when the heart contracts. It is the high number in a blood pressure measurement.",
        "timeFrame": "At inclusion, Day 1, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "Temperature",
        "timeFrame": "At inclusion, Day 1, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "Cardiac Frequency",
        "description": "The number of heart contractions or beats per unit of time. The normal values in adults at rest range between 60 and 100 beats per minit.",
        "timeFrame": "At inclusion, Day 1, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "Respiratory Frequency",
        "description": "Number of breaths the patient takes per minute.",
        "timeFrame": "At inclusion, Day 1, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "Oxygen Saturation",
        "description": "blood oxygen percentage. A healthy percentage of oxygen in the blood is between 95% and 100%.",
        "timeFrame": "At inclusion, Day 1, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "Hemoglobin",
        "description": "hemoglobin levels in the blood",
        "timeFrame": "At inclusion, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "Leucocytes",
        "description": "Leucocyte count a patient's blood.",
        "timeFrame": "At inclusion, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "Neutrophils",
        "description": "Neutrophils count a patient's blood.",
        "timeFrame": "At inclusion, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "Absolute Lymphocytes",
        "description": "lymphocyte count a patient's blood.",
        "timeFrame": "At inclusion, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "Activated Partial Thromboplastin Time",
        "description": "measurement of the number of seconds it takes for a clot to form in a patient's blood.",
        "timeFrame": "At inclusion, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "Fibrinogen Level",
        "description": "measurement of the level of fibrinogen in the blood (mg / dl), as a measure of assessing the severity of the disease.",
        "timeFrame": "At inclusion, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "Fragment D-dimer Assessment",
        "description": "Determination of the existence of the D-dimer fragment in blood as a measure of assessing the severity of the disease.",
        "timeFrame": "At inclusion, Day 3, Day 7, Day 14"
      },
      {
        "measure": "Glomerular Filtration Rate Assessment",
        "description": "estimation of how much blood passes per minute through the glomerular filters of the kidneys (ml/min).",
        "timeFrame": "At inclusion, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "Troponin I Assessment",
        "description": "measurement of the levels of troponin I proteins in the blood (ng/mL), as a measure of assessing the severity of the disease.",
        "timeFrame": "At inclusion, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "Procalcitonin Assessment",
        "description": "measurement of the levels of procalcitonin in the blood (ng/L), as a measure of assessing the severity of the disease.",
        "timeFrame": "At inclusion, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "C-reactive Protein Assessment",
        "description": "measurement of the level of c-reactive protein in the blood (mg/dl), as a measure of a change in inflammation",
        "timeFrame": "At inclusion, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "Lactate Dehydrogenase (LDH) Assessment",
        "description": "measurement of the level of lactate dehydrogenase in the blood (U/L), as a measure of assessing the severity of the disease.",
        "timeFrame": "At inclusion, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "Interleukin-6 Assessment",
        "description": "measurement of serum levels Interleukin-6 in pg/mL, as a measure of assessing the severity of the disease.",
        "timeFrame": "At inclusion, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "Ferritin Blood Assessment",
        "description": "measurement of the amount of ferritin (blood protein) in ng/ml in the blood, as a measure of assessing the severity of the disease.",
        "timeFrame": "At inclusion, Day 3, Day 7, Day 14, Day 21"
      },
      {
        "measure": "Percentage of Patients Requiring Admission to Intensive Care Units.",
        "description": "Percentage of patients requiring admission to intensive care units.",
        "timeFrame": "Day 21"
      },
      {
        "measure": "Mortality Rate at 15 Days",
        "description": "number of dead participants through day 15",
        "timeFrame": "Day 15"
      },
      {
        "measure": "Mortality Rate at 30 Days",
        "description": "number of dead participants through day 30",
        "timeFrame": "Day 30"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 26,
      "otherCount": 0,
      "totalCount": 28
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:37.637Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}